New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing
-
Tuya Inc. (TUYA) Announces Anchor Investment by 65 Equity Partners
-
Tuya Announces Anchor Investment by 65 Equity Partners
-
Emulate Energy and Smartcar Partner to Drive EV Utilization as Distributed Energy Resources
-
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A CVRx, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Form 144 CVRx, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 8A L P
-
Form 144 CVRx, Inc. Filed by: NEW ENTERPRISE ASSOCIATES VIII L P
-
Form SC 13G/A Tuya Inc. Filed by: New Enterprise Associates 14, L.P.
-
Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development
-
US autonomous truck startup Outrider raises $62 million to scale up
-
Outrider Closes $62 Million Series D Financing to Drive Growth of Yard Automation
-
Form SC 13D/A Inventiva S.A. Filed by: New Enterprise Associates 17, L.P.
-
Global Health Exhibition Opens its Doors Tomorrow to Record-Breaking 100,000+ Attendees to World's Premier Healthcare Transformation Event
-
Stride Annual Open Enrollment Research Reveals 73% of ACA Buyers Will Not Compare Plans Heading into 2025, Despite Anticipated Premium Increases
-
Inventiva SA (IVA) PT Lowered to $13 at H.C. Wainwright
-
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
-
Form SC 13D/A OnKure Therapeutics, Filed by: New Enterprise Associates 15, L.P.
-
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
-
ReCode Announces Two Key Additions to Scientific Advisory Board
-
Revelation Partners Deepens Healthcare Expertise with Two New Hires
-
Stride Publishes Study Revealing Financial Challenges Faced by Millions of Independent Workers
-
Lyft and Smartcar Partner to Tackle the Top Pain Point for EV Drivers — Range Anxiety
-
Form SC 13D MBX Biosciences, Inc. Filed by: New Enterprise Associates 17, L.P.
-
Functional Finance Secures $20M Series A Funding Led by Walkabout Ventures
-
Form 4 MBX Biosciences, Inc. For: Sep 16 Filed by: New Enterprise Associates 17, L.P.
-
Invenra Welcomes Three Industry Leaders to Its Board of Directors
-
DeltaStream Raises $15M in Series A Funding to Deliver the Future of Real-Time Stream Processing in Cloud
-
'AI godmother' Fei-Fei Li raises $230 million to launch AI startup
-
Habitat Health announces founding leadership team and more than $50 million in capital investments
-
HEAVY.AI Accelerates Big Data Analytics with Vultr's High-Performance GPU Cloud Infrastructure
-
On National Cellulite Day, New Omnibus Survey Results Reveal Cellulite Myths and Find Nearly 80% of Women with Cellulite on Their Buttocks and Thighs State Creams and Gadgets Don't Work Over the Long
-
CVRx (CVRX) Appoints Kevin Ballinger and Mitch Hill to its Board
-
CVRx Announces Appointment of Two New Board Members
-
Orby and Databricks Partner to Revolutionize Generative AI Automation for the Enterprise
-
Orby Expands Industry’s Leading Research, Machine Learning And Foundation Model Team
-
Moximed Completes Closing of Series D Financing for $91 Million to Accelerate Commercialization of MISHA® Knee System, an Implantable Shock Absorber for Knee Osteoarthritis
-
Form SC 13D/A Monte Rosa Therapeutics, Filed by: New Enterprise Associates 17, L.P.
-
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
-
Aligos Therapeutics Strengthens Board with Two New Independent Directors
-
Orby Launches ActIO the First Agentic AI Foundation Model to Set New Industry-Leading Performance Benchmarks
-
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
-
Clio announces US $900M investment at US $3B valuation to transform the legal experience for all
-
Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson's Disease Pipeline
-
Magenta Medical Closes $105M Financing Led by Novo Holdings
-
Form 144 Tuya Inc./ADR Filed by: New Enterprise Associates 14, L.P.
-
Hivebrite takes Community Engagement to the Next Level with the Acquisition of AI-powered Matching Engine Orbiit
-
ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center
-
Orby AI Raises $30 Million to Deliver the First Large Action Model for AI Automation Unlocking Unrivaled Enterprise Efficiencies
-
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer

